share_log

Protagenic Therapeutics' Reports Safety Data From Single Dose Portion Of Phase 1 Trial Involving PT00114

Protagenic Therapeutics' Reports Safety Data From Single Dose Portion Of Phase 1 Trial Involving PT00114

Protagenic Therapeutics 报告了涉及 PT00114 的 1 期试验单剂量部分的安全数据
Benzinga ·  05/22 21:03

No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to Commence

单剂量部分未报告临床相关不良事件,开始多剂量部分

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发